Table 1.
Allellic frequencies of CTLA-4 49A/G polymorphism among patient controls
| CTLA-4+49A/G | Allele frequencies | p | Odds ratio (95% CI) | |||||
| pSS | SSA+ and SSB+ | SSA+ only | Ac+ | Ac0 | Controls (n = 241) | |||
| Cohort 1 | n = 142 | n = 47 | n = 43 | n = 90 | n = 52 | pSS vs controls | ||
| A (Thr) | 208 (73) | 68 (72) | 61 (71) | 129 (72) | 79 (76) | 318 (66) | 0.036 | 1.41 (1.02–1.95) |
| G (Ala) | 76 (27) | 26 (28) | 25 (29) | 51 (28) | 25 (24) | 164 (34) | 0.036 | 0.70 (0.51–0.98) |
| Cohort 2 | n = 139 | n = 52 | n = 49 | n = 101 | n = 38 | Controls (n = 241) | ||
| A (Thr) | 173 (62) | 59 (57) | 66 (67) | 125 (62) | 48 (63) | 318 (66) | NS | 0.85 (0.62–1.15) |
| G (Ala) | 105 (38) | 45 (43) | 32 (33) | 77 (38) | 28 (37) | 164 (34) | NS | 1.17 (0.86–1.60) |
| Total | n = 281 | n = 99 | n = 92 | n = 191 | n = 90 | Controls (n = 241) | ||
| A (Thr) | 381 (68) | 127 (64) | 127 (69) | 254 (66) | 127 (71) | 318 (66) | NS | 1.08 (0.84–1.40) |
| G (Ala) | 181 (32) | 71 (36) | 57 (31) | 128 (34) | 53 (29) | 164 (34) | NS | 0.92 (0.71–1.19) |
Numbers in parentheses are percentages. pSS, primary Sjögren syndrome; Ac+, presence of anti SSB and/or anti-SSA; Ac0, absence of anti-SSA or anti-SSB antibody; CI, confidence interval; NS, not significant.